CLINICAL TRIALS PROFILE FOR OMACETAXINE MEPESUCCINATE
✉ Email this page to a colleague
All Clinical Trials for OMACETAXINE MEPESUCCINATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002574 ↗ | Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia | Completed | National Cancer Institute (NCI) | Phase 2 | 1994-09-01 | Phase II trial to study the effectiveness of homoharringtonine and interferon alfa in treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells. |
| NCT00003239 ↗ | Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | Completed | National Cancer Institute (NCI) | Phase 2 | 1998-03-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with cytarabine and homoharringtonine and biological therapy with interferon alfa in treating patients with chronic phase chronic myelogenous leukemia. |
| NCT00003239 ↗ | Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | Completed | M.D. Anderson Cancer Center | Phase 2 | 1998-03-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with cytarabine and homoharringtonine and biological therapy with interferon alfa in treating patients with chronic phase chronic myelogenous leukemia. |
| NCT00003694 ↗ | Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase | Completed | National Cancer Institute (NCI) | Phase 2 | 1999-03-01 | Phase II trial to study the effectiveness of homoharringtonine plus low-dose cytarabine in treating patients who have newly diagnosed chronic phase chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. |
| NCT00006364 ↗ | Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | Completed | National Cancer Institute (NCI) | Phase 2 | 1999-11-01 | Phase II trial to study the effectiveness of homoharringtonine in treating patients who have chronic phase chronic myelogenous leukemia. Drugs used in chemotherapy, such as homoharringtonine, work in different ways to stop cancer cells from dividing so they stop growing or die |
| NCT00114959 ↗ | Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) | Terminated | ChemGenex Pharmaceuticals | Phase 2 | 2005-10-01 | This will be an open label, multi-center study of up to 77 patients with CML in chronic, accelerated or blast phase who have developed resistance to or have failed previous treatment with Gleevec (imatinib mesylate). Because these patients may still be sensitive to Gleevec, adding Homoharringtonine may restore a response to Gleevec or the combined treatment may promote a better response than using Gleevec alone. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OMACETAXINE MEPESUCCINATE
Condition Name
Condition MeSH
Clinical Trial Locations for OMACETAXINE MEPESUCCINATE
Trials by Country
Clinical Trial Progress for OMACETAXINE MEPESUCCINATE
Clinical Trial Phase
Clinical Trial Sponsors for OMACETAXINE MEPESUCCINATE
Sponsor Name
